$25.26
+2.63 (+11.62%)
Open$23.10
Previous Close$22.63
Day High$26.10
Day Low$23.10
52W High$15.81
52W Low$9.81
Volume—
Avg Volume607.3K
Market Cap40.35M
P/E Ratio40.84
EPS$0.34
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-33.5% upside
Current
$25.26
$25.26
Target
$16.81
$16.81
$13.00
$16.81 avg
$24.93
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.65M | 7.80M | 6.88M |
| Net Income | -2,097,514 | -1,645,262 | -1,540,052 |
| Profit Margin | -27.4% | -21.1% | -22.4% |
| EBITDA | -2,154,773 | -2,236,853 | -1,912,817 |
| Free Cash Flow | -1,120,093 | -988,846 | -1,121,747 |
| Rev Growth | +8.4% | +22.8% | +24.7% |
| Debt/Equity | 0.85 | 0.67 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |